CMP: $90

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Amgen is a $69 Billion market cap company trading at a P/E of 16. Revenues have risen from $14.64 Billion to $15.58 Billion in the last 2 years. Profits have dipped from $4.60 Billion to $3.68 Billion in the last 2 years. Profit margins have slipped from 31% to 24% in the last 2 years. Recent quarter profits have bounced back nicely. With a balanced long term debt, its a decent bet.